ArticleEmerging microbes & infections2022

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron.

Yuanmei Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.